These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14984372)

  • 1. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Feb; 19(3):263-9. PubMed ID: 14984372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment.
    Seeger JD; Quinn S; Earnest DL; Lembo A; Kuo B; Rivero E; Walker AM
    BMC Gastroenterol; 2012 Nov; 12():171. PubMed ID: 23198861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: tegaserod.
    Camilleri M
    Aliment Pharmacol Ther; 2001 Mar; 15(3):277-89. PubMed ID: 11207504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ; Frampton JE; Croom KF
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL; Schoenfeld P
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
    Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A
    Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.
    Lin SR; Ke MY; Luo JY; Yuan YZ; Wang JY; diTommaso S; Walter V; Huang J
    World J Gastroenterol; 2007 Feb; 13(5):732-9. PubMed ID: 17278196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.
    Quigley EM; Wald A; Fidelholtz J; Boivin M; Pecher E; Earnest D
    Clin Gastroenterol Hepatol; 2006 May; 4(5):605-13. PubMed ID: 16678076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
    Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of tegaserod for the treatment of irritable bowel syndrome.
    Jones BW; Moore DJ; Robinson SM; Song F
    J Clin Pharm Ther; 2002 Oct; 27(5):343-52. PubMed ID: 12383135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of cholecystectomy in patients receiving tegaserod.
    Brinker A; Schech SD; Burgess M; Avigan M
    Drug Saf; 2007; 30(7):581-8. PubMed ID: 17604409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
    Müller-Lissner S; Kamm MA; Musoglu A; Earnest DL; Dunger-Baldauf C; Shetzline MA
    Am J Gastroenterol; 2006 Nov; 101(11):2558-69; quiz 2671. PubMed ID: 17090282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.